Global Renin-Angiotensin System Medicine Sales by Country

In 2023, South Korea, Greece, and Spain witnessed varied trends in Renin-Angiotensin System Medicine Sales per Capita with values of $39, $34.5, and $34.1 respectively. South Korea saw a 5.67% YoY increase, while Greece faced a decline of 7.23%. Spain had a modest rise of 3.8%. Additionally, New Zealand showed significant growth at 19.83%, and Denmark at 8.89%. These trends reflect differing regional demand and healthcare investments.

Future Trends

Future trends indicate potential volatility in markets such as Greece and Canada, with healthcare policy changes and economic factors playing pivotal roles. Emerging advancements in personalized medicine and regional health initiatives will likely influence sales dynamics, making it crucial to monitor healthcare reforms and economic conditions closely.

Top countries in Renin-Angiotensin System Medicine Sales by Country

# 10 Countries US Dollars PPP Per Capita Last Year YoY 5-years CAGR
1 1 South Korea 39 2023 +3.72% +5.67% View data
2 2 Greece 34.5 2023 -5.22% -7.23% View data
3 3 Spain 34.1 2023 +3.02% +3.8% View data
4 4 Germany 32.3 2023 +1.57% +3.2% View data
5 5 Hungary 28.4 2023 0% -0.14% View data
6 6 Canada 18.8 2023 -9.62% -4.36% View data
7 7 Austria 18.6 2023 -3.12% -4.07% View data
8 8 Chile 10.4 2023 0% +6.47% View data
9 9 Sweden 9.4 2023 +6.82% +8.68% View data
10 10 Norway 9.3 2023 -4.12% 0% View data

Top Countries about Cardiovascular Drug